Report
Adam Fleck
EUR 100.00 For Business Accounts Only

Mayne Continues to Face Generic Market Challenges; FVE to AUD 1.00

The negative 10-month trading update provided by no-moat Mayne Pharma follows a challenging half-year result reported in February, and was largely factored into our base case for fiscal 2019. However, continued competitive forces in generic pharmaceuticals in the U.S. results in a reduction in our fair value estimate to AUD 1.00 from AUD 1.05. Revenue in the key generic products segment is down 15% year to date primarily as result of increased competition and the negative effect on pricing. We n...
Underlying
Mayne Pharma Group Limited

Mayne Pharma is a pharmaceutical company focused on applying its drug delivery capabilities to commercialize branded and generic pharmaceuticals. Co. operates in four business units: Generic Products, which develops, manufactures, markets and distributes generic pharmaceutical products in the U.S.; Specialty Brands, which markets and distributes specialty branded pharmaceutical products in the U.S.; Metrics Contract Services, which provides contract pharmaceuticals development services and analytical services to third parties; and Mayne Pharma International, which develops, manufactures, markets and distributes branded and generic pharmaceutical products globally, excluding the U.S.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Adam Fleck

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch